Nathanael Gray spent his childhood in Zambia, Yemen, India and Sudan before returning to the US to attend high school at Berkeley High in California. Nathanael Gray received his PhD in organic chemistry from the University of California at Berkeley in 1999 where he discovered Purvalanol, one of the first selective inhibitors of cyclin-dependent kinases. He then moved to the Genomics Institute of the Novartis Research Foundation in San Diego, where after serving as a staff scientist and group leader of kinase inhibitor chemistry, he was named director of biological chemistry in 2001. Dr. Gray’s research team was responsible for the development of several clinical candidates, including BAF312 which is currently undergoing phase III clinical trials for the treatment of Multiple Sclerosis. Dr. Gray joined the faculty of Harvard Medical School and the Dana Farber Cancer Institute in 2006 to continue his research using synthetic chemistry and functional small molecule discovery to modulate biological pathways important in cancer. His research group has been responsible for the discovery of novel inhibitors of wild-type and mutant forms of EGFR (WZ4002), mTor (Torin1 and Torin 2), Bcr-Abl (GNF-2, GNF-5, HG-7-85-01), Mps1 (Mps1-IN-1 Mps1-IN-2), Erk5 (XMD8-92), b-Raf, LRRK2 (LRRK2-IN-1), Jnk1,2,3 (JNK-IN-7) and Ephrin kinases which have become widely used research tools and have inspired several drug discovery programs.